43 results about "Radiopaque agent" patented technology

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

Disclosed is a system for the treatment of cerebral aneurysms using a stent and a aneurysm pocket fill structure delivery system. One embodiment of the present invention uses a highly radiopaque, drug eluting stent that is deployed with its sidewall over the ostium of the aneurysm pocket. A fill structure delivery catheter is then advanced through the patient's vascular system until the catheter's distal end is situated within the aneurysm pocket. Compressed aneurysm pocket filling structures are then pushed through the fill structure delivery catheter. As the aneurysm pocket filling structures emerge from an opening in the catheter's distal end, they promptly expand so that their minimum dimension is sufficiently large so that they cannot pass through the spaces between the struts of the stent that cover the ostium of the aneurysm pocket.

The present invention is directed to an intravascular treatment for intracranial aneurysms. The invention consists of a patch stent and, also, a patch stent delivery system allowing one to rotate the stent to align the patch with the neck of the aneurysm. A self-expanding nitinol framework holds the patch in place, a radiopaque agent allows the patch location to be visualized and a pusher tube that is mechanically locked into the unexpanded stent is used to push the stent out of the catheter with rotational and longitudinal control necessary to align the patch with the aneurysm. A self-expanding framework is used to support a patch at the neck of the aneurysm. The patch is designed to reduce the blood circulation in the aneurysm and the stagnant blood will clot or thrombus. The thrombus will stop any current blood leakage into the brain and will dramatically reduce the possibility of future leaks or potentially deadly ruptures. Over time the thrombus will be absorbed and the volume of the aneurysm will shrink reducing pressure on surrounding tissue.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution, and a wetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guide wire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution and a wetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guidewire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution and a vetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guidewire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

A device and method provides a graft having a layer of synthetic non-metallic material including a first surface and a second surface spaced apart from the first surface. The device further includes a beading coupled to the layer and a radiopaque agent coupled to the beading. Another device and method provides a implantable prosthesis having a stent frame, a first inner layer and a second outer layer defining a central axis. The implantable prosthesis further includes a beading coupled to at least one the layers.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution, and a wetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guide wire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution and a wetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guidewire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

Methods for making biomaterials for use as a tissue sealant, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from a composition comprising at least a first and a second precursor molecule, wherein:i) the first precursor molecule is a poly(ethylene glycol) based polymer having x nucleophilic groups selected from the group consisting of thiol or amino groups, wherein x is greater than or equal to 2ii) the second precursor molecule is of the general formula:A-[(C3H6O)n—(C2H4O)m—B]i wherein m and n are integers from 1 to 200i is greater than 2A is a branch pointB is a conjugated unsaturated groupThe precursors are selected based on the desired properties of the biomaterial. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to reduce, inhibit, or contain loss of a biological fluid or gas in a patient.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics. The stent has a plurality of hoop components interconnected by a plurality of flexible connectors. The hoop components are formed as a continuous series of substantially longitudinally or axially oriented radial strut members and alternating substantially circumferentially oriented radial arc members. The geometry of the struts and arcs is such that when the stent is expanded, it has very high strains within a relatively small region. This strain localization results in what is often referred to as “hinging”, where the hinge is the small region within which the strains are very high.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

A flow directed catheter for use in medical diagnostic or therapeutic procedures having a strain relief segment between the relatively stiff proximal section of the catheter and the floppy distal tip portion in which the strain relief segment is formed of a polymeric material containing a radiopaque agent.

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics. The stent has a plurality of hoop components interconnected by at least one flexible connector. The hoop components are formed as a continuous series of alternating substantially longitudinally oriented strut members and connector junction struts, whereas the longitudinal strut is connected to the connector junction strut by alternating substantially circumferentially oriented arc members.

The present invention provides a composition based on calcium aluminate cement (CAC) for application in endodontics, comprising: (a) a cement—Al2O3 (>68.5 wt %), CaO (<31 wt %), SiO2 (0.3-0.8 wt %), MgO (0.4-0.5 wt %), and Fe2O3 (<0.3 wt %); (b) additives: dispersant at a content of 0.4 to 0.8% by weight of the cement, a plasticizer at a content of 2.0 to 4.0% by weight of the cement, and a radiopaque agent at a content of 20 to 35% by weight of the cement; and (c) water, wherein water / cement ratio lies in the range of 0.19-0.24 in the presence of additives. Cementitious product obtained thereof, after setting time, is also disclosed and characterized by enhanced properties when compared to the most used commercial repair cement, MTA.

In accordance with the present invention, a high intensity radiopaque contrast agent is disclosed. The agent may be coated on or incorporated within bulk material which may then be subsequently utilized to fabricate a radiopaque medical device. Primary effects through chemistry include higher radiopaque concentrations per unit weight of the radiopaque element or agent. Secondary effects include selective placement of the radiopaque elements which may further enhance the radiopacity of the device with reduced requirements of the radiopaque agent. Such a radiopaque contrast agent may be produced in various forms such as a dendrimer and / or incorporated as the end groups of polymeric chain. In addition one can incorporate biological and / or pharmaceutical agents in combination with the present invention.

A method of replacing a nucleus pulposus material wherein curable nucleus pulposus material is injected into a balloon in an intervertebral space. The balloon has an inlet port and an outlet port that are connected to a pressure-measuring device. After the catheter is placed in the intervertebral space, the balloon is filled with a radio-opaque solution until the desired balloon volume is attained. The nucleus replacement material is then fed into the inlet port of the balloon, while the radiopaque agent is allowed to leave via the outlet port. Once the balloon is completely filled and curing of the curable nucleus replacement material is accomplished, the catheter and ports are removed, and the annular defect can be sealed.

High radiopacity is achieved in a polymeric marker by combining a polymeric resin, a powdered radiopaque agent having uniformly shaped particles of a specific particle size distribution, and a wetting agent. The method to produce the marker calls for the blending and pelletization of these materials followed by extrusion onto support beading. The resulting supported tubing is subsequently cut to length with the beading still in place. After ejection of the beading remnant the marker is slipped into place on the device to be marked and attached by melt bonding. Marking of a guide wire allows lesions to be measured while the marking of balloon catheters allow the balloon to be properly positioned relative to a lesion.

Methods and apparatus are provided for improved administration of brachytherapy in the treatment of prostate disease. More particularly, a prostate visualization device is provided comprising a catheter coupled to at least one deployable member at the distal end of the catheter. The deployable member is preferably manufactured from a shape memory alloy having a petal-shaped configuration suitable for engaging and defining the proximal region of a patient's bladder. The deployable member may comprise tubing filled with air or other radiopaque agents to facilitate ultrasonic imaging of the deployable members near the bladder / prostate junction.

Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. The polymeric materials may include additives such as drugs or other bioactive agents as well as radiopaque agents. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

A medical device is constructed from a polymeric composition having properties such as increased visibility of the device and the ability to deliver therapeutic and other agents. The device is constructed with additives incorporated into the polymeric structure, such as a material that increases visibility of the device, while still maintaining desired mechanical characteristics such as high radial stiffness, minimized recoil values, and improved flexibility. The device can assume a wide range of geometries that are adaptable to various loading conditions In order to include performance-enhancing additives to the medical device without affecting mechanical performance, the additives are localized in discrete regions of a polymer structure from which a medical device will be formed. For example, a medical device can be prepared from a polymer form such as a tube containing radiopaque agent localized at its ends or in a desired pattern along the device.

Disclosed is a monofilament allowing contrast X-ray radiography. At least part of the monofilament is formed of a thermoplastic resin containing a radiopaque agent. The monofilament contains the radiopaque agent in the thermoplastic resin in a content of 30 to 80% by mass, and has a Young's modulus of 0.1 to 5.0 cN / dtex and a fineness of 500 to 20000 dtex.

An absorbable sponge containing a contrasting agent (e.g, radiopaque agent) that can be introduced to a biopsy tract or other puncture wound site is provided. The contrasting agent permits identification of the site by fluoroscopy or other imaging techniques.

Methods for making biomaterials for augmentation of soft and hard tissues, kits containing precursors for forming the biomaterials, and the resulting biomaterials are described herein. The biomaterials are formed from at least a first and a second precursor component. The first precursor component contains at least two nucleophilic groups, and the second precursor component contains at least two electrophilic groups. The nucleophilic and electrophilic groups of the first and second precursor components form covalent linkages with each other at physiological temperatures. The precursors are selected based on the desired properties of the biomaterial. In the preferred embodiment, the first precursor is a siloxane. Optionally, the biomaterials contain additives, such as thixotropic agents, radiopaque agents, or bioactive agents. In the preferred embodiment, the biomaterials are used to augment at least one vertebra of the spine (vertebroplasty).